Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

Biogen and Sage will shut down the ongoing study of SAGE-324. On today's stock market, Sage stock collapsed 20.6% to 10.38. Biogen stock gained a fraction, closing at 226.03.

Sage Therapeutics, Inc. and Biogen Inc. announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 as a potential treatment in essential tremor.

On Thursday, Sage Therapeutics Inc. (NASDAQ:SAGE) announced that Biogen Inc (NASDAQ:BIIB) had terminated its rights under the collaboration and license agreement with Sage, which was specific to ...

Biogen shares (BIIB) were down 0.1% premarket on Wednesday and have dropped 13.3% in the year to date, while Sage's stock is down nearly 40% so far this year. -Eleanor Laise ...

Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development. The companies are evaluating next steps, if any, for other ...

Biogen, Sage discontinue neuro candidate after mid-stage setback. Jul. 24, 2024 7:43 AM ET Sage Therapeutics, Inc. (SAGE) Stock, BIIB Stock By: Dulan Lokuwithana, SA News Editor. Play (1min) ...

BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share. Such an offer reflects Biogen’s interest in reducing its ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) Wednesday said the Phase 2 KINETIC 2 study evaluating SAGE-324 to treat essential tremor (ET) did not meet primary goal. Essential ...

Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by ...

Shares of Sage Therapeutics Inc. fell more than 18% premarket on Wednesday after a failed trial dealt a blow to the company’s collaboration with Biogen Inc.